ConjuChem Biotechnologies, Inc.

ConjuChem Biotechnologies, Inc.

ConjuChem Biotechnologies Inc. (ConjuChem) is a Canadian biotechnology company dedicated to the discovery of therapeutics with an initial focus on diabetes. The Company is focused on discovering and developing new drugs based on its technology platforms called Drug Affinity Complex (DAC) and Preformed Conjugate-Drug Affinity Complex (PC-DAC). The Company has developed the DAC Technology, a platform that enables the rapid creation of improved, patentable drugs from existing small organic compounds or peptides. The Company also designs drugs to treat an array of pathologies, such as diabetes, cancer and human immunodeficiency virus (HIV). ConjuChem has multiple research programs in-house and has one product in clinical trials.

Contact Details

Office Address

ConjuChem Biotechnologies, Inc.
225, President-Kennedy Avenue, Third Floor, Suite 3950
Montreal, Quebec, Canada H2X3Y8
Phone: (514) 844-5558
Fax: (514) 844-1119



Jacques R. Lapointe

President and CEO

Mark D. Perrin

Business Reviews for ConjuChem Biotechnologies, Inc.

Related Companies